 |
Companies | Products |
|
|
Products | |
Diseases | |
Trials |  |
News |  |
| «123 |
- | Journal: BCL6 inhibition: a chronic GVHD twofer. (Pubmed Central) - Aug 15, 2019
No abstract available
- | Journal: PRMT5 interacts with the BCL6 oncoprotein and is required for germinal center formation and lymphoma cell survival. (Pubmed Central) - Aug 1, 2019
Inhibition of PRMT5 in B-cell lymphoma lines led to significant upregulation of BCL6 target genes, and the concomitant inhibition of both BCL6 and PRMT5 exhibited synergistic killing of BCL6-expressing lymphoma cells. Our studies identify PRMT5 as a novel regulator of the GC reaction and highlight the mechanistic rationale of co-targeting PRMT5 and BCL6 in lymphoma.
- | Journal: Development of a Novel B-Cell Lymphoma 6 (BCL6) PROTAC To Provide Insight into Small Molecule Targeting of BCL6. (Pubmed Central) - Jul 4, 2019
Analysis of subcellular fractions also showed incomplete BCL6 degradation in all fractions despite having measurable PROTAC concentrations, together providing a rationale for the weak antiproliferative response seen with both BCL6 inhibitor and degrader. In summary, we have developed potent and selective BCL6 inhibitors and a BCL6 PROTAC that effectively degraded BCL6, but both modalities failed to induce a significant phenotypic response in DLBCL despite achieving cellular concentrations.